U.S. drug developer Capricor places Duchenne drug trial on hold
The trial, named "HOPE-2", was testing the company's lead experimental drug CAP-1002, according to California-based Capricor's website.
New Delhi: Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy(DMD), a muscle-wasting disorder, citing a safety review.
The review follows a severe allergic reaction during infusion of the drug, the company said in a filing. The patient responded well to medical treatment and is currently asymptomatic.
The company has notified the U.S. Food and Drug Administration and is working with the agency on a mitigation plan, it said.
The trial, named "HOPE-2", was testing the company's lead experimental drug CAP-1002, according to California-based Capricor's website.
DMD is a rare, genetic disorder that hampers muscle movement, mainly in men, affecting one in every 3,500 to 5,000 males. More than 90 per cent of patients become wheelchair-bound by age 15.
Also Read: Affimed puts on hold cancer drug trial after patient death
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd